| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2005-02-0564 |
| P8608 | Fatcat ID | release_rzcspbpsjbactlmkz4oepyfw5u |
| P698 | PubMed publication ID | 15985537 |
| P5875 | ResearchGate publication ID | 7757489 |
| P50 | author | Peter Hillmen | Q48086375 |
| P2093 | author name string | Jason Chan | |
| Stephen J Richards | |||
| Christopher F Mojcik | |||
| Russell P Rother | |||
| Anita Hill | |||
| Dupe Elebute | |||
| Judith C Marsh | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2559-2565 | |
| P577 | publication date | 2005-06-28 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria | |
| P478 | volume | 106 |
| Q40734548 | A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA. |
| Q59800432 | A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein |
| Q30409539 | A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors |
| Q33373289 | A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome |
| Q33419128 | Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome |
| Q37307880 | Anticomplement therapy. |
| Q37810065 | Autoimmune hemolytic anemia: classification and therapeutic approaches |
| Q81737067 | Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with previous cerebral venous thrombosis |
| Q86701446 | Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry |
| Q36756854 | Complement in immune and inflammatory disorders: therapeutic interventions |
| Q36187306 | Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria |
| Q39142842 | Complementopathies |
| Q39566121 | Cross‐sectional validation study of patient‐reported outcomes in patients with paroxysmal nocturnal haemoglobinuria |
| Q50635749 | Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. |
| Q37580829 | Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. |
| Q51068337 | Diagnosing PNH with FLAER and multiparameter flow cytometry. |
| Q28256613 | Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria |
| Q48256943 | Diseases of complement dysregulation-an overview |
| Q33398742 | Drugs that inhibit complement |
| Q44109055 | Eculizumab for paroxysmal nocturnal haemoglobinuria |
| Q24193045 | Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria |
| Q24201126 | Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria |
| Q81520078 | Eculizumab in paroxysmal nocturnal haemoglobinuria |
| Q37810103 | Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria |
| Q40107597 | Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization |
| Q41091207 | Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes |
| Q50648020 | Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria |
| Q53459321 | Eculizumab. |
| Q37956407 | Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria |
| Q48078070 | Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria |
| Q34462881 | Hemoglobinuria misidentified as hematuria: review of discolored urine and paroxysmal nocturnal hemoglobinuria |
| Q33398967 | Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report |
| Q87233834 | Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results |
| Q39554119 | Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan |
| Q50496730 | Intra- and interlaboratory variability of paroxysmal nocturnal hemoglobinuria testing by flow cytometry following the 2012 Practical Guidelines for high-sensitivity paroxysmal nocturnal hemoglobinuria testing |
| Q36654336 | Investigational treatments for multiple myeloma |
| Q41953134 | Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases |
| Q37098212 | Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria |
| Q37955206 | Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria |
| Q47266287 | Myasthenia gravis: the role of complement at the neuromuscular junction |
| Q90116210 | Novel insights into the treatment of complement-mediated hemolytic anemias |
| Q38998217 | Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed. |
| Q88093383 | Paroxysmal nocturnal haemoglobinuria |
| Q34431429 | Paroxysmal nocturnal hemoglobinuria |
| Q35093962 | Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes |
| Q38156229 | Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition |
| Q36732489 | Paroxysmal nocturnal hemoglobinuria in children |
| Q42821159 | Paroxysmal nocturnal hemoglobinuria presenting as cerebral venous sinus thrombosis: a case report |
| Q83375667 | Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience |
| Q54919143 | Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs |
| Q42036462 | Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents |
| Q28085020 | Platelets in inflammation and atherogenesis |
| Q36509944 | Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. |
| Q38658582 | Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry |
| Q36751227 | Presentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience |
| Q34537391 | Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice |
| Q36947184 | Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo |
| Q37032625 | Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression |
| Q90170407 | Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
| Q36574160 | Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria |
| Q36840839 | Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria |
| Q36780187 | Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria |
| Q48925994 | Recurrent cerebral ischaemic events in the setting of paroxysmal nocturnal haemoglobinuria. |
| Q34626253 | Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial |
| Q84959423 | Strategy for bone marrow transplantation in eculizumab-treated paroxysmal nocturnal hemoglobinuria |
| Q33586908 | Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study |
| Q38850489 | Targeting the complement cascade: novel treatments coming down the pike. |
| Q38089295 | The Complement Cascade in Kidney Disease: From Sideline to Center Stage |
| Q99571087 | The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies |
| Q37462959 | The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab |
| Q26851705 | Therapeutic regulation of complement in patients with renal disease where is the promise? |
| Q26853483 | Thrombosis in paroxysmal nocturnal hemoglobinuria |
Search more.